Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer
Authors Wang N, Guo H, Dong Z, Chen Q, Zhang X, Shen W, Bao Y, Wang X
Received 9 April 2018
Accepted for publication 11 June 2018
Published 12 September 2018 Volume 2018:10 Pages 3463—3471
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Kenan Onel
Nan Wang,1,* Huihui Guo,2,* Zhaohuo Dong,1 Qiuqiang Chen,2 Xilin Zhang,2 Weiyun Shen,2 Ying Bao,2 Xiang Wang2
1Medical Department, Huzhou Hospital of Traditional Chinese Medicine, Huzhou, People’s Republic of China; 2First Affiliated Hospital, Huzhou Teachers College, The First People’s Hospital of Huzhou, Huzhou, People’s Republic of China
*These authors contributed equally to this work
Purpose: A series of microRNAs (miRNAs) have been identified as associated with the survival of patients with non-small-cell lung cancer (NSCLC). The aim of the present study was to explore whether combination of these experimentally validated individual miRNA biomarkers could be used to further increase their prognostic power in NSCLC.
Patients and methods: Based on previously validated NSCLC prognostic miRNAs, gene signatures that could discriminate high-risk subgroups with poor clinical outcome in four NSCLC miRNA expression datasets (GSE13937, GSE16025, The Cancer Genome Atlas Lung Adenocarcinoma, and TCGA lung squamous cell carcinoma) were developed using the SurvMicro tool. The potential of the miRNA signature established was validated by quantitative real-time PCR analysis of clinical NSCLC samples, and its prognostic power evaluated using the survivalROC method.
Results: We developed two miRNA signatures with prognostic significance for NSCLC, comprising 12- and 7-miRNAs. The 7-miRNA signature (miR-148b, miR-365, miR-32, miR-375, miR-21, miR-125b, and miR-155) was a subset of a 12-miRNA set that retained prognostic power across NSCLC cohorts. Compared with previously established miRNA signatures, our 7-miRNA signature has similar potential, while comprising fewer miRNA components. The prognostic ability of the 7-miRNA signature was validated experimentally in an independent NSCLC cohort using real-time PCR (HR=3.4847, 95% CI=1.3693–8.8680, P=0.0092), and this signature, combined with tumor pathological stage, had superior prognostic ability compared with tumor stage alone.
Conclusion: Our data indicate that the established 7-miRNA signature is simple, robust, and may have greater clinical prognostic utility for patients with NSCLC.
Keywords: lung cancer, gene signature, overall survival, The Cancer Genome Atlas, TCGA, risk classification
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]